Publications

15 Aug 2017
News

CEOs have to take a stand, says former Medtronic CEO

February 1998 (Revised May 1998)
Case

Merck-Medco: Vertical Integration in the Pharmaceutical Industry

By: V. Kasturi Rangan and Marie Bell

Records the analyses and actions taken by Merck Pharmaceuticals in its acquisition of Medco, a channel intermediary (called "pharmacy benefit manager"). While many of its competitors seem to be faring poorly, Merck seems to have managed the Medco integration superbly. View Details

Keywords: Vertical Integration; Organizational Change and Adaptation; Competitive Strategy; Marketing Channels; Mergers and Acquisitions; Pharmaceutical Industry

May 2004 (Revised June 2004)
Case

Brief Biographical Note on P. Roy Vagelos

By: Nitin Nohria and Bridget Gurtler

Provides background biographical information on P. Roy Vagelos, chief executive officer of Merck Pharmaceuticals. Teaching Purpose: To chart the development of a leader in the pharmaceutical industry. View Details

Keywords: Biography; Teaching; Leadership Development; Mission and Purpose; Personal Development and Career; Ethics; Pharmaceutical Industry

14 Aug 2017
News

Extremely disappointed Trump didn't agree with Frazier

02 Nov 2020
Working Paper Summaries

Accounting for Organizational Employment Impact

Keywords: by David Freiberg, Katie Panella, George Serafeim, and T. Robert Zochowski

September 2020
Case

Merck: COVID-19 Vaccines

By: Willy C. Shih

COVID-19 infections were still climbing across the U.S. and many other parts of the world in September 2020, and it seemed that every time Ken Frazier, the CEO of Merck & Co. consented to an interview in recent months he always seemed to hear the same question,... View Details

Keywords: Vaccines; COVID-19 Pandemic; Health Pandemics; Health Testing and Trials; Innovation and Management; Innovation Strategy; Technological Innovation; Business Strategy; Product Launch; Pharmaceutical Industry

October 2020
Teaching Plan

Merck: COVID-19 Vaccines

By: Willy C. Shih

COVID-19 infections were still climbing across the U.S. and many other parts of the world in September 2020, and it seemed that every time Ken Frazier, the CEO of Merck & Co. consented to an interview in recent months he always seemed to hear the same question,... View Details

Keywords: Vaccines; Health Pandemics; Health Testing and Trials; Innovation and Management; Innovation Strategy; Research and Development; Business Strategy; Pharmaceutical Industry; United States

April 2012 (Revised May 2012)
Case

Merck: Operating Science-Based Business

By: Ananth Raman, Inga Maurer and William Schmidt

Merck is known for its commitment to investing in basic R&D. Are Merck's long-term investments justifiable when the firm faces extreme earnings pressure? View Details

Keywords: Science-Based Business; Management; Research and Development; Business and Shareholder Relations; Operations; Pharmaceutical Industry; United States

May 2011 (Revised July 2012)
Exercise

Remicade/Simponi: Confidential Instructions for Johnson & Johnson

By: Guhan Subramanian and Rhea Ghosh

This two-party negotiation exercise features a real-life dispute between Merck and Johnson & Johnson regarding European distribution rights to two highly lucrative drugs. View Details

Keywords: Price; Rights; Agreements and Arrangements; Negotiation Deal; Problems and Challenges; Risk and Uncertainty; Europe

20 Jul 2020
News

How Much Will it cost? And 5 Other Questions Congress Could Push COVID-19 Vaccine Makers to Answer

21 Jul 2020
News

Where do COVID-19 vaccine players stand on pricing? So far, it's no profit, slight profit or undecided

March 1994 (Revised March 1995)
Case

Astra/Merck Group

By: Frank V. Cespedes and Marie Bell

Astra/Merck (A/M), originally a joint venture of AB Astra and Merck & Co., is preparing to be an independent company in 1993. Since the company does not engage in basic research and development of drugs, it is essentially a distribution organization. Fundamental to... View Details

Keywords: Cost vs Benefits; Marketing Strategy; Distribution; Performance Evaluation; Research and Development; Risk and Uncertainty; Sales; Competitive Strategy; Pharmaceutical Industry

January 1989 (Revised September 1995)
Case

MSDI-Alcala de Henares, Spain

By: Timothy A. Luehrman

Merck & Co., Inc. is evaluating a proposed cost-saving investment by its Spanish subsidiary. The case introduces techniques of discounted cash flow valuation analysis in a multicurrency setting. Can be used to teach basic international parity conditions as they relate... View Details

Keywords: Business Subsidiaries; Cash Flow; Cost Management; Currency; Investment; Management Analysis, Tools, and Techniques; Valuation; Spain

April 2009
Case

Merck: Managing Vioxx (A)

By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred

This two-class case series allows students to stand in the shoes of CEO Ray Gilmartin during the unfolding stages of a reputational crisis. Merck's mission statement claims to "put patients first," but the company is widely criticized for putting profit before patient... View Details

Keywords: Ethics; Crisis Management; Reputation; Decision Choices and Conditions; Customers; Business or Company Management; Cost vs Benefits; Corporate Accountability; Business and Shareholder Relations; Business and Stakeholder Relations; Customer Focus and Relationships; Pharmaceutical Industry

January 1987 (Revised May 1989)
Case

Merck-Banyu

By: Timothy A. Luehrman

Merck acquired control of Banyu in 1983. This was the first acquisition by outsiders of a major publicly traded Japanese company. This case is focused on valuing strategic investments in an environment of global competition. The case is complex because of the... View Details

Keywords: Acquisition; Investment; Globalization; Governing Rules, Regulations, and Reforms; Industry Structures; Negotiation Deal; Public Ownership; Competition; Valuation; Japan

January 2017
Case

Bayer AG: Bidding to Win Merck's OTC Business

By: Benjamin C. Esty, Marc Baaij and Arjen Mulder

Shortly after submitting their best and final offer to acquire Merck's Consumer Care Division (a collection of "over-the-counter" (OTC) products with sales totaling $2 billion), the Bayer M&A team was given a chance to revise their bid because another potential... View Details

Keywords: Acquisition; Bidding Strategy; Valuing Synergies; Negotiations; Corporate Strategy; Business Unit Strategy; Bidding Process; Discounted Cash Flow; Cross-border M＆A; Tax Shields; Valuation; Competitive Strategy; Auctions; Bids and Bidding; Germany; United States; United Kingdom

March–April 2023
Article

The New-Collar Workforce

By: Colleen Ammerman, Boris Groysberg and Ginni Rometty

Many workers today are stuck in low-paying jobs, unable to advance simply because they don’t have a bachelor’s degree. At the same time, many companies are desperate for workers and not meeting the diversity goals that could help them perform better while also reducing... View Details

Keywords: Diversity; Recruitment; Social Issues; Higher Education; Competency and Skills